Phase-II-study with EAP (etoposide, adriamycin, cis-platinum) in patients with primary inoperable gastric cancer and advanced disease.
Preusser
P
P
Chirurgische Klinik und Poliklinik, Westfälische Wilhelms-Universität, Münster, FRG.
Wilke
H
H
Achterrath
W
W
Fink
U
U
Neuhaus
P
P
Meyer
J
J
Meyer
H J
HJ
van de Loo
J
J
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D013274:Stomach Neoplasms / Q000188:drug therapy*
D005047:Etoposide; D004317:Doxorubicin; D002945:Cisplatin